Femasys released its Q1 2026 results on May 8, and the headline number told a challenging story: sales of $424,889 came in well below the $767,000 estimate, a miss of roughly 45%. The stock slipped 4.3% on the day to $0.43, despite posting an EPS beat of $0.07. That gap between a surprise on earnings and a miss on revenue captures the central tension heading into next week's scheduled earnings call on May 15 — the commercial ramp of FemaSeed is underway, but the pace has so far disappointed.
The short positioning backdrop is more benign than the revenue miss might suggest. Short interest is running at 3.5% of the free float — meaningful but not extreme — and it has actually been unwinding. Over the past month, shares short fell roughly 14%, retreating from a peak near 2.45 million shares in late March to around 2.0 million now. Borrow costs have eased alongside: the cost to borrow is at 7.6%, down sharply from a mid-April spike that briefly touched 20.5%. Availability is ample at 437% of short interest, meaning the lending pool is far from stressed. The short score of 54, sitting in a relatively neutral range, reflects a position that is being actively covered rather than built. The borrow market tells a story of shorts walking away, not piling in.
The Street remains constructive in rating but increasingly reserved on price. The most recent coverage was Lake Street's initiation in early March 2026 at Buy with a $1.50 target — a target already more than 3x the current price at $0.43. Earlier initiations (Laidlaw at $6.50 in November 2025, HC Wainwright at $8.00 in August 2025) reflect targets set when the stock traded at materially higher levels. Those targets should be treated with caution given the distance from current trading. The bull case centres on European FemBloc revenue coming online in the first half of 2026 and distributor leverage from existing FemaSeed relationships. The bear case is blunter: the company may need roughly $60 million in additional financing to sustain operations into 2038, and clinical or efficacy setbacks could accelerate that clock.
The most notable fundamental development this week was the announcement on May 5 that FemaSeed had its first revenue-generating commercial use in an OB/GYN setting as a first-line infertility treatment — the news that drove the stock up nearly 12% on the week heading into results. That milestone matters more for the product narrative than for near-term revenue, but it gives management a concrete data point to frame the commercial trajectory on the May 15 call.
Prior earnings reactions have been mixed and volatile. The November 2025 print produced a one-day drop of nearly 20%. The March 2026 event delivered a one-day gain of almost 11%. That range of outcomes in both directions points to a setup where news flow — not the direction of shorts or borrow cost — will drive the near-term tape. The May 15 call, positioned just one week after a significant revenue miss paired with a commercial milestone announcement, is the event to watch.
See the live data behind this article on ORTEX.
Open FEMY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
